About Celeris Therapeutics
Celeris Therapeutics is a company based in Graz (Austria) founded in 2020 by Christopher Trummer and Jakob Hohenberger.. Celeris Therapeutics has raised $4.4 million across 2 funding rounds from investors including i&i Bio, Pace Ventures and APEX Ventures. Celeris Therapeutics operates in a competitive market with competitors including Relay Therapeutics, Atomwise, Genesis Therapeutics, Unnatural Products and neoX Biotech, among others.
- Headquarter Graz, Austria
- Founders Christopher Trummer, Jakob Hohenberger
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.4 M (USD)
in 2 rounds
-
Latest Funding Round
$4.4 M (USD), Seed
Feb 10, 2022
-
Investors
i&i Bio
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Funding Insights of Celeris Therapeutics
Celeris Therapeutics has successfully raised a total of $4.4M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $4.4 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $4.4M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2022 | Amount | Seed - Celeris Therapeutics | Valuation | i&i Bio | |
| Mar, 2021 | Amount | Seed - Celeris Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Celeris Therapeutics
Celeris Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include i&i Bio, Pace Ventures and APEX Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage venture capital investments are made by Pace Ventures.
|
Founded Year | Domain | Location | |
|
Venture capital funding is offered for deep-tech and medical startups.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Celeris Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Celeris Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Celeris Therapeutics Comparisons
Competitors of Celeris Therapeutics
Celeris Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Relay Therapeutics, Atomwise, Genesis Therapeutics, Unnatural Products and neoX Biotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery platform is developed to study protein motion.
|
|
| domain | founded_year | HQ Location |
AI-driven platform for structure-based drug discovery is provided.
|
|
| domain | founded_year | HQ Location |
Computational platform for AI-driven small molecule drug discovery is developed.
|
|
| domain | founded_year | HQ Location |
Peptides are engineered via computational biology for undruggable targets.
|
|
| domain | founded_year | HQ Location |
Protein-protein interactions are researched and characterized to aid drug discovery.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Celeris Therapeutics
Frequently Asked Questions about Celeris Therapeutics
When was Celeris Therapeutics founded?
Celeris Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Celeris Therapeutics located?
Celeris Therapeutics is headquartered in Graz, Austria. It is registered at Graz, Styria, Austria.
Who is the current CEO of Celeris Therapeutics?
Christopher Trummer is the current CEO of Celeris Therapeutics. They have also founded this company.
Is Celeris Therapeutics a funded company?
Celeris Therapeutics is a funded company, having raised a total of $4.4M across 2 funding rounds to date.
What does Celeris Therapeutics do?
Celeris Therapeutics was founded in 2020 in Graz, Austria, within the biotechnology sector. An AI-driven platform is utilized by the company to enable degradation of undruggable protein targets through methods such as PROTACs and molecular glues. Operations involve computer-based drug design and discovery, supported by the One cloud platform, which facilitates targeted therapeutic development for specific biological challenges.
Who are the top competitors of Celeris Therapeutics?
Celeris Therapeutics's top competitors include Atomwise, Genesis Therapeutics and Unnatural Products.
Who are Celeris Therapeutics's investors?
Celeris Therapeutics has 5 investors. Key investors include i&i Bio, Pace Ventures, APEX Ventures, R42 Group, and Longevitytech.fund.